Fritextsökning
Artiklar per år
Innehållstyper
-
Ålder som hinder – Så hittar du nya jobbmöjligheter efter 55
Trots lång erfarenhet har många svårt att ta sig vidare i karriären efter 55. Karriärcoachen Tina Persson råder att lyfta fram överförbara kunskaper och att vårda sitt nätverk för att bryta igenom åldersfördomarna.
-
New findings on the diseases that crushed Napoleon’s army
As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever during the retreat from Russia.
-
A cluster contribution to European life science innovation and competitiveness?
-
How the Nobel discovery is used in drug development
Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how this finding is being applied in today’s drug development, and what challenges remain.
-
Sarah Lidé: ”Artificial intelligence must not replace authentic interactions”
Artificial intelligence must never become a replacement for authentic, even if messy, interactions with our fellow humankind, Sarah Lifé, Deputy CEO at Medicon Village Innovation, writes in a column.
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required during treatment can be a heavy burden for both patients and healthcare systems. Dr. Andri Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.
-
Karriärcoachen: Så får du AI att söka jobbet åt dig
För att använda AI effektivt måste vi ändra vårt tankesätt för hur vi kommunicerar. Annars får vi bara döda motivationsbrev och döda resuméer. Det anser karriärcoachen Tina Persson som ser AI som sätt att effektivisera och förbättra vårt jobbsök. Så länge vi lär oss kommunicera med tekniken.
-
”Sverige riskerar tappa forskartalanger – dags att bygga broar”
Debatten om arbetskraftsinvandring är het i Sverige. Men när vi diskuterar kvoter och restriktioner missar vi en avgörande aspekt: Vad händer med de internationella forskare, doktorander och postdocs, som redan finns här, och som utgör en central del av vår spetskompetens inom life science? Om det resonerar Tina Persson i en debattartikel.
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in the US reveals a common denominator: all are gene therapies administered as one-time treatments.
-
BMS and venture capital giant form new company
The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company will develop treatments for autoimmune diseases where there is currently a lack of effective therapies.
-
Svenske Martin Kulldorff bland nya vaccinrådgivare – utnämnd av Kennedy
USA:s hälsominister Robert Kennedy Jr. utsåg på onsdagen åtta nya ledamöter till CDC:s rådgivande vaccinkommitté (ACIP), efter att plötsligt ha avskedat hela den tidigare panelen på 17 experter.
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. "We invested for 25 years while everyone else laughed at us. Now everyone wants to join the game," says Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk.
-
Trump in new push to lower drug prices
U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in other wealthy countries — something he claims could reduce prices by 30 to 80 percent.
-
Rovtidskriftsjägaren om sin ärkefiende: ”Ondskans imperium”
Han myntade begreppet rovtidskrifter och gjorde ett första försök att kartlägga deras utbredning. Nu berättar bibliotekarien Jeffrey Beall om konsekvenserna det fick för honom. Det här är del fyra i Life Science Swedens artikelserie om rovtidskrifter.
-
Mikael Kubista back with new venture after turbulent exit
Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work – the company Tataa Biocenter. “Not only did they take our company away from us. They followed up by showering us with lawsuits,” he says.
-
From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool
Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals on his podcasts.
-
Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field
Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. Life Science Sweden reached out to him.
-
An organ seldom in the spotlight – but utterly vital
The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclinical research about kidney diseases. “They are probably one of the most complicated organs in the body, and I like a challenge”, she says.
-
Aqilion's licensing journey: From Merck partnership to new opportunities
Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO Sarah Fredriksson and is directed at biotech companies aiming to find a good licensing partner.
-
Career coach on salaries: “There is no right or wrong”
What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes this is an important consideration.
-
A tiny animal with great importance
From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious career – as an increasingly important model organism in medical research.
-
Who pays for Rebecca Doe – and all of us?
Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it
-
The art of successful licensing – “A lot has to align”
Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies: to succeed with a licensing deal.
-
Ukraine war fuels rise of totally resistent bacteria
War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.